Generics company Actavis loses lawsuit; NIH looking to fund drug delivery researchers;

> A New Jersey court ruled that Actavis ($ACT) generics violate 7 Depomed patents of its Gralise (gabapentin) tablets for the management of postherpetic neuralgia, which are based on its proprietary Acuform drug delivery technology. Release | Story

> Drug delivery specialist EastGate Acquisitions said that it is trying to acquire the licensing rights to develop and manufacture an intraoral insulin formulation. Release

> The FDA issued a Class I recall of Enhancement Medical's Expression intranasal splint, saying it is dangerous when injected subcutaneously, especially when used off-label as a dermal filler. Story

> The U.S. National Institutes of Health is inviting scientists to apply for funding of research into platform delivery technologies for nucleic acid therapeutics. Announcement